Corporate Actions
Material events companies report to the SEC on Form 8-K: mergers, dividends, buybacks, splits, management changes, bankruptcies and more. Enter a ticker for one company's history, or browse the latest across the market.
ImmunityBio (IBRX)
1 8-K filing| Filed | Action | What the filing says | SEC |
|---|---|---|---|
| Feb 23, 2026 |
Earnings
Item 2.02Item 9.01
|
Results of Operations and Financial Condition. On February 23, 2026, ImmunityBio, Inc. (the Company) issued a press release providing a business update and announcing its financial results for the fourth quarter and year…Results of Operations and Financial Condition. On February 23, 2026, ImmunityBio, Inc. (the Company) issued a press release providing a business update and announcing its financial results for the fourth quarter and year ended December 31, 2025, and its financial position as of December 31, 2025. The full text of the Company’s press release is furnished as Exhibit 99.1 hereto. The information furnished pursuant to Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filings of the Company made under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date of this Current Report, r |
Filing 8-K |
Each 8-K is classified by its most significant item; hover an item number for its title. Classification and excerpts are read automatically and can be wrong; the filing on SEC.gov is the authority. For research, not investment advice.